“We are thrilled with the significant progress recently achieved throughout our business,” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “As we expected, enrollment in our ongoing SHIELD II Phase 3 pivotal trial for D-PLEX100 has begun to ramp up, and we continue to anticipate top-line results from this study in the second half of 2024. We have also generated new highly compelling preclinical data with OncoPLEX that demonstrate its potential in oncology and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PYPD:
- PolyPid enrolls 100th patient in SHIELD II phase 3 trial
- PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
- PolyPid Ltd. (PYPD) Q4 Earnings Cheat Sheet
- PolyPid files to sell 6.74M ordinary shares for holders
- PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024